Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Babali Nursing Research Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice)
Ekayanti, Ni Luh Putu Serly
Unknown Affiliation
Nursing

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Formulasi Sediaan Krim Pelembab Ekstrak Air Buah Semangka (Citrullus lanatus) Ekayanti, Ni Luh Putu Serly; Darsono, Farida Lanawati; Wijaya, Sumi
Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Vol. 6 No. 1 (2019)
Publisher : Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33508/jfst.v6i1.2011

Abstract

Watermelon is a tropical fruit which rich of carbohydrates such as sucrose, glucose and fructose that can moisturized the skin. Carotenoids such as lycopene in watermelons can acts as an antioxidant which protected skin from free radicals. Moisturizer are preparations used to improve dry skin. These preparations may decrease the Trans Epidermal Water Loss (TEWL) by forming a thin layer of fat on the surface of the skin as a barrier and restore skin softness. Watermelon extracts in this study are formulated into moisturizing cream. This study aims to determine the effect of the increasing concentration of the watermelon extract against its physical quality, effectiveness, safety, acceptability and cream stability. The watermelon extract obtained using is fresh fruit juice thickened with waterbath thermostat temperature ≤ 800C. Watermelon extract concentration used was 10% (Formula 1), 20% (Formula 2) and 30% (Formula 30. Evaluation of the cream includes the physical quality test; effectiveness test which; safety test; acceptability test and stability test. The results of this study showed the increasing concentrations of watermelon extract affect the results of the evaluation of moisturizing cream were organoleptic, pH, viscosity, dispersive power, adhesion, water washing power, effectiveness, and aseptability. Preparations which have the best quality are formula 3 containing extract 30%.
The Effectiveness of SGLT-2 Inhibitors vs GLP-1 Receptor Agonists in Enhancing Kidney Function and Glycemic Control for Diabetes Mellitus Patients with CKD: A Narrative Review Wibawa, Putu Ngurah Pradnya; Ekayanti, Ni Luh Putu Serly
Babali Nursing Research Vol. 7 No. 1 (2026): January
Publisher : Babali Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37363/bnr.2026.71506

Abstract

Introdution: Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) are highly interconnected, impacting global health. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) offer promising benefits for glycemic control, cardiovascular health, and kidney protection. This review compares their effectiveness in enhancing kidney function and glycemic control for T2DM patients with CKD. Methods: A narrative review was conducted using the PICO framework, searching the PubMed database and online search (ScienceDirect and Google Scholar) for English-language observational research articles published between 2020 and 2025. Articles focused on SGLT2i and GLP-1RA therapies in T2DM patients with CKD, assessing kidney function and glycemic control. Fifteen articles were selected from an initial 706. The keyword use is “comparing” AND “effectiveness” AND “SGLT-2 inhibitor” AND “GLP-1 RA” AND “kidney function” AND “glycemic control” AND “T2DM” AND “CKD” AND “patients”. Results: SGLT2 inhibitors consistently demonstrated strong renal protective effects, including slower eGFR decline and reduced kidney failure progression. GLP-1RAs excelled in glycemic control, weight management, and cardiovascular event reduction. While SGLT2i generally appeared superior for direct renal protection, some studies suggested comparable renal outcomes. Real-world data largely supported these findings, enhancing clinical applicability. Conclusion: SGLT2 inhibitors are recommended for T2DM patients with CKD, especially those at higher renal risk. GLP-1RAs are valuable for glycemic control, weight, and cardiovascular benefits. Their complementary mechanisms suggest potential for additive benefits in combination therapy, necessitating further research to optimize patient outcomes.
Co-Authors Farida Lanawati Darsono Sumi WIjaya, Sumi Wibawa, Putu Ngurah Pradnya